Clinical aspects of the management of HIV lipodystrophy

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 3, 2008, Pages 113-119

  Weirzbicki, Anthony S ^a   Purdon, Scott D ^b   Hardman, Timothy C ^c   Kulasegaram, Ranjababu ^a   Peters, Barry S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Niche Science and Technology Ltd   (United Kingdom)

Author keywords

Cardiovascular risk; Cholesterol; Diabetes; Human immunodeficiency virus; Lipodystrophy; Treatment; Triglycerides

Indexed keywords

ABACAVIR; ACETYLCARNITINE; ANABOLIC AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMIVUDINE; METFORMIN; NEVIRAPINE; NICOTINIC ACID; NUCLEOSIDE ANALOG; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TETRACYCLINE; THIAMINE; THYMIDINE DERIVATIVE; UBIQUINONE; UNINDEXED DRUG; VITAMIN; ZALCITABINE; ZIDOVUDINE;

ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIFE EXPECTANCY; LIFESTYLE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOATROPHY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 47349113866     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514080080030201     Document Type: Review

References (91)

1. Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
2. Bozzette SA, Ake CF, Tam HK et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
3. World Health Organisation and Joint United Nations Programme on HIV/ AIDS. Treating 3 million by 2005: making it happen, the WHO strategy. Geneva: World Health Organisation; 2003.
4. Carr A, Samaras K, Chisholm DJ et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-3.
5. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
6. Mallon PW, Cooper DA, Carr A. HIV-associated lipodystrophy. HIV Med 2001;2:166-73.
7. Wierzbicki AS, Purdon SD, Hardman TC et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice, Curr Med Res Opin 2008;24:609-24.
8. Milinkovic A, Martinez E. Current perspectives on HIV-associated lipodystrophy syndrome. J Antimicrob Chemother 2005;56:6-9.
9. Grunfeld C, Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003;37(suppl 2):S43-S46.
10. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
11. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
12. Behrens GM, Stoll M, Schmidt RE. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23(1):57-76.
13. Hakeem L, Campbell IW, Bhattacharyya DP. HIV-associated lipodystrophy - a new metabolic syndrome. Br J Diabetes Vasc Dis 2008; 8:129-34.
14. Wanke CA, Falutz JM, Shevitz A et al. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002; 34:248-59.
15. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003;32:298-302.
16. Paparizos VA, Kyriakis KP, Botsis C et al. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000;14:903-05.
17. Sharp M. Metabolic complications associated with HIV disease. Posit Aware 2003;14(2):32-6.
18. Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005; 21:1717-25.
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. Mondy K, Overton ET, Grubb J et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007;44:726-34.
21. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000;30 Suppl 2:S135-S142.
22. Heath KV, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231-9.
23. Galli M, Ridolfo AL, Adorni F et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29(1):21-31.
24. Heath KV, Hogg RS, Singer J et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 2002; 30:440-7.
25. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005;118 (suppl 2):S23-S28.
26. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
27. Kotler DP, Thea DM, Heo M et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr 1999;69:432-9.
28. Jaya G, Lutchman N, Crowther N. Metabolic Complications of ART in Black South Africans, 14th Conference on Retrovirus' and Opportunistic Infections Los Angeles USA 2007 Abstract 796
29. Saves M, Raffi F, Capeau J et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002;34:1396-405.
30. Maisonneuve C, Igoudjil A, Begriche K et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther 2004; 9:801-10.
31. Haubrich RH, Riddler S, diRienzo G et al. Metabolic outcomes of ACTG 5142: a prospective, randomised, phase III trial of NRTI-, PI-, and NNRTI-sparing regimes for initial treatment of HIV-1 infection 2007.
32. Cameron DW, da Silva B, Arribas J et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV/3TC. 2007.
33. Grunfeld C, Pang M, Doerrler W et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
34. Badiou S, De Boever CM, Dupuy AM et al. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ ritonavir-containing regimen. AIDS 2003;17:772-4.
35. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-62.
36. Lafeuillade A, Alessi MC, Poizot-Martin I et al. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992; 5:127-31.
37. Seminari E, Pan A, Voltini G et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162:433-8.
38. Mercie F, Thiebaut R, Lavignolle V et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34(1):55-63.
39. Purnell JQ, Zambon A, Knopp RH et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14(1):51-7.
40. Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks. J Assoc Nurses AIDS Care 2002;13(2):86-7.
41. Noor MA, Parker RA, O'Mara E et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137-44.
42. Sanne I, Piliero F, Squires K et al. Results of a Phase 2 Clinical Trial at 48 Weeks (Al424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects. J Acquir Immune Defic Syndr 2003;32(1):18-29.
43. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.
44. Martinez E, Garcia-Viejo MA, Blanco JL et al. Impact of switching from HIV type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
45. Piketty C, Peytavin G, Trylezinski A et al. Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. HIV Med 2002;3:287-9.
46. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-46.
47. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.
48. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-4.
49. Carpentier A, Patterson BW, Uffelman KD et al. Mechanism of highly active antiretroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005;178:165-72.
50. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003;33:321-8.
51. Brambilla AM, Novati R, Calori G et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17:1993-5.
52. Zimmet P. Epidemiology of diabetes mellitus and associated cardiovascular risk factors: focus on human immunodeficiency virus and psychiatric disorders. Am J Med 2005;118(suppl 2):3S-8S.
53. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004;4:763-77.
54. Fleischman A, Johnsen S, Systrom D et al. Effects of NRTI, stavudine, on insulin sensitivity and mitochondrial function in muscle of healthy adults. 14th Conference on Retrovirus' and Opportunistic Infections Los Angeles USA 2007 Abstract 43.
55. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondral toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.
56. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711-19.
57. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.
58. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.
59. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr 2003;33:571-6.
60. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003;18:1039-52.
61. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.
62. Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112:3713-21.
63. Wilson PW, Meigs JB, Sullivan L et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74.
64. Roubenoff R, Schmitz H, Bairos L et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 2002;34:390-3.
65. Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-19.
66. Wierzbicki AS. Low HDL-cholesterol: Common and under-treated, but which drug to use? Int J Clin Pract 2006;60:1149-53.
67. Brinkman K, ter Hofstede HJ, Burger DM et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
68. Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14(1):37-49.
69. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493-505.
70. Martinez E, Conget I, Lozano L et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
71. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185:1251-60.
72. Sattler F. Body habitus changes related to lipodystrophy. Clin Infect Dis 2003;36(Suppl 2):S84-S90.
73. Lindström J, Ilanne-Parikka F, Peltonen M et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368:1673-9.
74. Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000;284:472-7.
75. Blazes DL, Decker CF. Symptomatic hyperlactataemia precipitated by the addition of tetracycline to combination antiretroviral therapy. Lancet Infect Dis 2006;6:249-52.
76. Gavrila A, Hsu W, Tsiodras S et al. Improvement in highly active anti-retroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomised, double-blinded, placebo-controlled trial. Clin Infect Dis 2005; 40:745-9.
77. Prasithsirikul W, Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thai 2004;87:166-72.
78. Sutinen J, Hakkinen AM, Westerbacka J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207.
79. Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy 2007;27:1449-55.
80. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2002;41:1195-211.
81. Mallon PW, Miller J, Kovacic JC et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men -a randomized, placebo-controlled study. AIDS 2006; 20:1003-10.
82. Badiou S, Merle De BC, Dupuy AM et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172:273-9.
83. Nystrom T, Bratt G, Sjoholm A. Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance. J Intern Med 2002;252:570-4.
84. Dube MP, Wu JW, Aberg JA et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther 2006;11:1081-9.
85. Samson SL, Pownall HJ, Scott LW et al. Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemp Clin Trials 2006;27:518-30.
86. Lee JH, Chan JL, Sourlas E et al. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006;91:2605-11.
87. Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 2004;38:448-57.
88. Mulligan K, Grunfeld C, Hellerstein MK et al. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956-62.
89. Wanke C, Gerrior J, Kantaros J et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103.
90. Schwarz JM, Mulligan K, Lee J et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2002;87:942.
91. Falutz J, Allas S, Blot K et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70.